ID: hypothesis-h-SDA-2026-04-26-gap-20260426
Hypothesis
Plasma NfL Elevation Secondary to BBB-Associated Transport Dysfunction Enables Longitudinal Neurodegeneration Tracking
Neurofilament light chain (NfL) is released from damaged neurofilaments into the extracellular space, flowing into CSF and ultimately into peripheral blood via degraded BBB transport mechanisms.
neurodegeneration
EvidenceStrong (65%)📖 30 cit🗣 1 debates✓ 9 support✗ 2 oppose
⚠ Low Validation Senate Quality Gates →
🧪 Overview
Neurofilament light chain (NfL) is released from damaged neurofilaments into the extracellular space, flowing into CSF and ultimately into peripheral blood via degraded BBB transport mechanisms. Early BBB disruption increases permeability of neurofilament-derived peptides into circulation, causing disproportionate plasma NfL elevation relative to CSF levels. This makes plasma NfL a sensitive indicator of BBB permeability-augmented neurodegeneration, enabling peripheral blood-based disease progression monitoring. Multiple FDA-cleared platforms (Simoa, Elecsys, Lumipulse) provide validated detection.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD A["Neurofilament damage"] --> B["NfL release to extracellular space"] B --> C["NfL flow into CSF"] D["BBB disruption"] --> E["Increased BBB permeability"] C --> E E --> F["Peripheral transport into blood"] F --> G["Plasma NfL elevation"] G --> H["FDA-cleared detection platforms"] H --> I["Simoa and Elecsys and Lumipulse"] I --> J["Sensitive quantification"] J --> K["Longitudinal monitoring"] K --> L["Neurodegeneration tracking"] G --> L D --> A A --> D L --> M["Disease progression outcomes"]
⚖️ Evidence
⚖️ Evidence Matrix9 supports2 contradicts
Supports
Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts.
Supports
Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
Supports
Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK Biobank.
Supports
Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.
Supports
Development, maintenance and disruption of the blood-brain barrier.
Supports
Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders.
Supports
Proteolytic cleavage of damaged neurofilaments releases NfL into the extracellular space
Contradicts
NfL elevation is non-specific to neurodegeneration (also elevated in trauma, stroke)
Contradicts
Neurofilament light chain as a biomarker in neurological disorders.
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — NEFL
No curated PDB or AlphaFold mapping for NEFL yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for NEFL from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for NEFL.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▼ 0.5%
Volatility
High
0.1224
Events (7d)
2
Price History
▼24.3%💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If BBB-associated NfL elevation reflects transport dysfunction, then serial plasma NfL will rise before cognitive decline in longitudinal cohorts, with the rate correlating with BBB imaging endpoints | In 2-year longitudinal cohort (n≥120), rising plasma NfL precedes MMSE decline by 6-12 months; NfL slope correlates with DCE-MRI Ktrans reduction (r<-0.4) but n | — no observation — | pending | 0.78 |
| If BBB dysfunction causes plasma NfL elevation through impaired transport, then NfL levels will correlate inversely with BBB integrity markers (CSF/serum albumin ratio) and directly with transcytosis | In MCI/early AD patients (n≥80), plasma NfL correlates with Qalb (r <-0.5, p<0.001) and with circulating endothelial microvesicles (r>0.5, p<0.001), but shows n | — no observation — | open | 0.82 |
🔮 Falsifiable Predictions (2)
openconf —
If BBB dysfunction causes plasma NfL elevation through impaired transport, then NfL levels will correlate inversely with BBB integrity markers (CSF/serum albumin ratio) and directly with transcytosis markers (CAV1, SLC2A1) in early AD patients, but not with neuronal injury sources unrelated to BBB.
Predicted outcome: In MCI/early AD patients (n≥80), plasma NfL correlates with Qalb (r <-0.5, p<0.001) and with circulating endothelial microvesicles (r>0.5, p<0.001), b
Falsification: Plasma NfL does not correlate with BBB integrity markers; levels remain driven entirely by neuronal injury markers (CSF tau, neurogranin), indicating transport mechanism is not operative.
pendingconf —
If BBB-associated NfL elevation reflects transport dysfunction, then serial plasma NfL will rise before cognitive decline in longitudinal cohorts, with the rate correlating with BBB imaging endpoints (DCE-MRI Ktrans) but not with concurrent neurodegeneration markers.
Predicted outcome: In 2-year longitudinal cohort (n≥120), rising plasma NfL precedes MMSE decline by 6-12 months; NfL slope correlates with DCE-MRI Ktrans reduction (r<-
Falsification: NfL trajectory is driven entirely by parenchymal neurodegeneration (hippocampal atrophy, CSF tau) with no independent contribution from BBB imaging changes, indicating transport mechanism does not con
Parent Context
▸Metadata
| _origin | {'url': None, 'type': 'internal', 'tracked_at': '2026-04-27T16:04:24.783608'} |
| description | Neurofilament light chain (NfL) is released from damaged neurofilaments into the extracellular space, flowing into CSF and ultimately into peripheral blood via degraded BBB transport mechanisms. Early |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.